Harbin ADE Pharmaceutical

Harbin ADE Pharmaceutical is a Chinese pharmaceutical company specializing in the development and manufacturing of treatments for cardiovascular and cerebrovascular diseases. A subsidiary of Harbin Gloria Pharmaceuticals, the company is most recognized for its flagship product, Aodejin (Deproteinized Calf Blood Extract Injection), which is widely utilized in China for treating cerebral ischemia and traumatic brain injuries. The company operates high-standard GMP-certified manufacturing facilities and contributes significantly to its parent company's portfolio in the neurological and vascular therapeutic areas. Harbin ADE focuses on both biological extracts and chemical drug formulations to address critical needs in hospital-based acute care.